Search Results - Stephane Champiat

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade by Olivier Lambotte, Jean-Marie Michot, Stephane Champiat, Francois-Xavier Danlos, Aurélien Marabelle, Romain Guitton, Ariane Laparra, Noemie Chanson, Sabine Messayke

    Published in Journal for ImmunoTherapy of Cancer (2025-09-01)
    Get full text
    Article


  2. 2

    Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors by Stephane Champiat, Francois-Xavier Danlos, Aurélien Marabelle, Yohann Loriot, Julia Delahousse, Kaïssa Ouali, Santiago Ponce, Laurent Mathiot, David Combarel, Justin Cagnat, Sophie Broutin

    Published in Journal for ImmunoTherapy of Cancer (2024-05-01)
    Get full text
    Article


  3. 3

    715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study) by Stephane Champiat, Francois-Xavier Danlos, Volker Kunzmann, Martin Wermke, Aude de Gassart, Daniel Olive, Patrick Brune, Emmanuel Valentin, Johann De Bono, Paul Frohna, Marina Iché, Maelle Mairesse, Celine Leparquier, Katrien Lemmens

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  4. 4

    Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines by Joachim Alexandre, Jennifer Cautela, Stéphane Ederhy, Ghandi Laurent Damaj, Joe‐Elie Salem, Fabrice Barlesi, Laure Farnault, Aude Charbonnier, Mariana Mirabel, Stéphane Champiat, Alain Cohen‐Solal, Ariel Cohen, Charles Dolladille, Franck Thuny

    Get full text
    Article


  5. 5

    Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types by Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard

    Published in Cancer Medicine (2020-04-01)
    Get full text
    Article


  6. 6

    Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors by Yan Zhang, Andrés Cervantes, Stephane Champiat, Aurélien Marabelle, Patricia LoRusso, Jason J Luke, Robert Haddad, David J Pinato, Dejan Juric, María de Miguel, Won Seog Kim, Xiaobin Yuan, Peter J Hosein, Anupam M Desai, Yuanxin Rong

    Published in Journal for ImmunoTherapy of Cancer (2025-02-01)
    Get full text
    Article


  7. 7

    Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology by Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug

    Published in Journal for ImmunoTherapy of Cancer (2023-03-01)
    Get full text
    Article


  8. 8

    Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis by Stéphane Ederhy, Stéphane Ederhy, Joe-Elie Salem, Joe-Elie Salem, Joe-Elie Salem, Joe-Elie Salem, Laurent Dercle, Abrar Saqif Hasan, Marion Chauvet-Droit, Pascal Nhan, Samy Ammari, Samy Ammari, Bruno Pinna, Alban Redheuil, Samia Boussouar, Stephane Champiat, Laurie Soulat-Dufour, Ariel Cohen, Ariel Cohen

    Published in Frontiers in Oncology (2021-05-01)
    Get full text
    Article


  9. 9

    First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore

    Published in Journal for ImmunoTherapy of Cancer (2023-03-01)
    Get full text
    Article


  10. 10

    716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or ga... by Jean-Yves Blay, Antoine Italiano, Stephane Champiat, Paolo Antonio Ascierto, Manish Sharma, Jeeyun Lee, Luis Paz-Ares Rodriguez, Keun-Wook Lee, Yoon-Koo Kang, Drew Rasco, Edith A Perez, Mariano Ponz-Sarvise, Lu Xu, Jean-Philippe Spano, Coya Tapia, Ecaterina Dumbrava, Kathleen Moore, Jason Ptacek, Michele Magni, Alfonso Cortes Salgado, Ming Yin, Agnese Losurdo, Antoine Deleuze, Mark D Pegram, Ardaman Shergill, Alexander I Spira, Michael N Alonso, Joan Albanell Mestres, Marta GilMartin, Arielle Heeke, Ana Oaknin Benzaquen, Ignacio Ortego Zabalza, Haeseong Park, Cecile Vicier, Ivan Victoria, Benjamin Weinberg, Bob T Li

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


Search Tools: